Well he did quickly report both of our posts and had them

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Boussard & Gavaudan Holding Limited: Overview Boussard & Gavaudan Holding Limited is an investment company focused on generating substantial returns for its shareholders through strategic investments and active management. The company has garnered attention due to its robust performance in the market. Here, we delve into the estimated Net Asset Value (NAV) and key...

Erwin Chemerinsky to Discuss Power Among Government Branches One of the leading experts in constitutional law, Erwin Chemerinsky, will be the keynote speaker for an upcoming lecture at the University of Houston Law Center. His lecture, titled "Constitutional Separation of Powers," promises to provide insightful exploration into the allocation of power among the...

Cytokinetics got buzzed about back when H.C. Wainwright slapped a strong Buy rating on 'em, setting a price target of $90 per share. Analysts were all in, believing aficamten could really shake things up for obstructive Hypertrophic Cardiomyopathy (oHCM) patients. Remember that SEQUOIA-HCM Phase 3 trial? Yeah, that’s where they showed some serious cardiac remodeling...

Alright, let's cut to the chase: Century Therapeutics, Inc. (NASDAQ: IPSC) is shuffling its deck with some heavyweight appointments—new blood, new vibes. Morgan Conn, Ph.D., struts in as Chief Financial Officer while Chad Cowan, Ph.D., dons the Chief Scientific Officer cape. This isn't just a warm body swap; it's a strategic play aiming to steer the company deeper into...

The Rise of BitMine Immersion Technologies Inc. Shares of BitMine Immersion Technologies Inc. (NASDAQ: BMNR) are experiencing upward momentum as the company shares recent achievements. This crypto treasury company has reported significant increases in its cryptocurrency assets, which have garnered attention across financial markets. Recent Developments in Crypto Holdings...